Retrospective analysis of a large cohort of pediatric and adult ADEM patients finds relapses are not uncommon.
Acute disseminated encephalomyelitis (ADEM) usually is a monophasic demyelinating disorder, predominantly observed in children. To assess actual outcomes in a large U.S. cohort, researchers retrospectively analyzed data from four U.S.-based pediatric multiple sclerosis (MS) centers. The analysis included 228 patients (47% male; 122 children; age range, 1–72) initially diagnosed with ADEM and followed for a median 24 months (range, 0–277).
International Pediatric MS Study Group criteria were met in 70% of pediatric cases and 47% of adult cases; not meeting the criteria was most often due to absence of encephalopathy. Most patients (58%) had infectious symptoms or vaccination within 4 weeks before presentation. The disease course was monophasi…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)